(Q36841072)

16 August 2017

1 reference

title

Thiazolidinediones in dermatology (English)

1 reference

16 August 2017

Alan S Boyd

1

1 reference

16 August 2017

publication date

1 June 2007

1 reference

International Journal of Dermatology

16 August 2017

published in

1 reference

16 August 2017

volume

46

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

557-563

1 reference

Pioglitazone: a promising therapy for psoriasis

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Nuclear peroxisome proliferator-activated receptors and thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

The effect of PPAR?? ligands on the proliferation and apoptosis of human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

The retinoids and cancer prevention mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Angioneurotic edema as a side effect of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Interventions for managing antiretroviral therapy-associated lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Pioglitazone-induced myofibroblast cell death: implications for cutaneous scarring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03273.X

10.1111/J.1365-4632.2007.03273.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference